Tissue Regenix Group PLC 2023 LTIP Grant (6727A)

TIDMTRX

RNS Number : 6727A

Tissue Regenix Group PLC

23 January 2024

Tissue Regenix Group plc

("Tissue Regenix" or "the Group")

2023 LTIP Grant

Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces that Daniel Lee, Chief Executive Officer, and David Cocke, Chief Financial Officer, were each granted an award of restricted share units ("RSUs") with respect to ordinary shares in the capital of the Company ("Ordinary Shares") on 21 March 2023, under the Company's existing Long-Term Incentive Plan, following the publication of its 2022 results.

Daniel Lee was awarded 19,807,390 RSUs (subsequently reduced to 198,073 RSUs following the Company's share consolidation that became effective on 28 April 2023) and David Cocke has been awarded 15,367,803 RSUs (subsequently reduced to 153,678 RSUs), where each RSU that vests shall represent the right to receive payment of one Ordinary Share. The exercise price of the RSUs was 0.1p per Ordinary Share (subsequently adjusted to 10p). The RSUs are subject to continued service over a period of three years and satisfaction of customary performance conditions relating to growth in total shareholder return, annual revenue targets, annual profitability targets and personal performance targets, further details of which will be set out in the Company's 2023 Annual Report.

Following the grant of these options, Daniel Lee and David Cocke hold options over a total of 756,897 and 514,002 RSUs respectively representing 1.1% and 0.7% of the current issued share capital respectively.

For more information:

 
 Tissue Regenix Group plc                                      www.tissueregenix.com 
 David Cocke, Chief Financial Officer                                via Walbrook PR 
 
 Cavendish Capital Markets Limited (Nominated 
  Adviser and Broker) 
  Emily Watts/Geoff Nash/George Dollemore - Corporate 
   Finance 
 Nigel Birks/Harriet Ward - ECM 
 
 Walbrook PR (Financial PR and IR)                          Tel: [phone] 
 Charlotte Edgar / Alice Woodings                       [e-mail] 
 
 

About Tissue Regenix ( www.tissueregenix.com )

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL(R)') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn-out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In August 2017 Tissue Regenix acquired CellRight Technologies(R), a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and soft tissue scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.

Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMRs") and persons closely associated ("PCA") with them.

 
  1   Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                   Daniel Lee 
     ---------------------  ------------------------------------------- 
 2    Reason for the notification 
     ------------------------------------------------------------------ 
 a)   Position/status        CEO 
     ---------------------  ------------------------------------------- 
 b)   Initial notification   Initial notification 
       /Amendment 
     ---------------------  ------------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ------------------------------------------------------------------ 
 a)   Name                   Tissue Regenix Group plc 
     ---------------------  ------------------------------------------- 
 b)   LEI                     213800PNOD5UHQUFJI36 
     ---------------------  ------------------------------------------- 
 4    Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of 
       transaction; (iii) each date; and (iv) each place where 
       transactions have been conducted 
     ------------------------------------------------------------------ 
 a)   Description            Restricted share units ("RSUs") with 
       of the financial       respect to ordinary shares in the capital 
       instrument,            of the Company of 0.1p 
       type of instrument 
     ---------------------  ------------------------------------------- 
 b)   Identification         GB00B5SGVL29 
       code 
     ---------------------  ------------------------------------------- 
 c)   Nature of the          Issue of options 
       transaction 
     ---------------------  ------------------------------------------- 
 d)   Price(s) and           Volume(s): 
       volume(s)              19,807,390 RSUs 
                              Price: 0.1 pence per RSU 
     ---------------------  ------------------------------------------- 
 d)   Aggregated 
       information             19,807,390 
       - Aggregated            GBP19,807.39 
       volume 
       - Price 
     ---------------------  ------------------------------------------- 
 e)   Date of the            21 March 2023 
       transactions 
     ---------------------  ------------------------------------------- 
 f)   Place of the           Outside of a trading venue 
       transaction 
     ---------------------  ------------------------------------------- 
 
 
  1   Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                   David Cocke 
     ---------------------  ------------------------------------------- 
 2    Reason for the notification 
     ------------------------------------------------------------------ 
 a)   Position/status        CFO 
     ---------------------  ------------------------------------------- 
 b)   Initial notification   Initial notification 
       /Amendment 
     ---------------------  ------------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ------------------------------------------------------------------ 
 a)   Name                   Tissue Regenix Group plc 
     ---------------------  ------------------------------------------- 
 b)   LEI                     213800PNOD5UHQUFJI36 
     ---------------------  ------------------------------------------- 
 4    Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of 
       transaction; (iii) each date; and (iv) each place where 
       transactions have been conducted 
     ------------------------------------------------------------------ 
 a)   Description            Restricted share units ("RSUs") with 
       of the financial       respect to ordinary shares in the capital 
       instrument,            of the Company of 0.1p 
       type of instrument 
     ---------------------  ------------------------------------------- 
 b)   Identification         GB00B5SGVL29 
       code 
     ---------------------  ------------------------------------------- 
 c)   Nature of the          Issue of options 
       transaction 
     ---------------------  ------------------------------------------- 
 d)   Price(s) and           Volume(s): 
       volume(s)              15,367,803 RSUs 
                              Price: 0.1 pence per RSU 
     ---------------------  ------------------------------------------- 
 d)   Aggregated 
       information             15,367,803 
       - Aggregated            GBP15,367.80 
       volume 
       - Price 
     ---------------------  ------------------------------------------- 
 e)   Date of the            21 March 2023 
       transactions 
     ---------------------  ------------------------------------------- 
 f)   Place of the           Outside of a trading venue 
       transaction 
     ---------------------  ------------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHDXLFLZFLLBBL

(END) Dow Jones Newswires

January 23, 2024 12:24 ET (17:24 GMT)